Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Operating Expenses:
Research and development	$ 528,355	$ 2,261,060	$ 3,458,657	$ 6,267,598
General and administrative	829,406	732,688	2,693,293	4,325,851
Total Operating Loss	(1,357,761)	(2,993,748)	(6,151,950)	(10,593,449)
Other Income/(Expense):
Gain on settlement of lawsuit			825,000
Research and development tax credit			42,685
Investment income	4,932	7,511	16,657	24,261
Interest expense	(256,173)	(125,256)	(697,214)	(226,622)
Net Loss	(1,609,003)	(3,111,493)	(5,964,823)	(10,795,810)
Dividend paid-in kind to preferred shareholders		(50)		(14,107)
Net Loss Applicable to Common Shareholders	$ (1,609,003)	$ (3,111,543)	$ (5,964,823)	$ (10,809,917)
Basic and Diluted Loss Per Common Share	$ 0.00	$ (0.01)	$ (0.02)	$ (0.03)
Weighted Average Number of Common Shares Outstanding - Basic and Diluted	383,256,742	370,546,735	380,754,529	368,722,485